Earlier this month, Heron Therapeutics resubmitted an application to approve its postoperative pain anesthetic.

On Oct. 28, the biotech said the U.S. Food and Drug Administration accepted the application, with a decision due by March 26.

The FDA kicked back the first application in April, citing manufacturing issues.

Heron’s HTX-011 lessened pain to a greater degree than a placebo and the anesthetic bupivacaine while hitting safety marks in late-stage clinical trials, according to the company.